Vaccines for Virus from Bunyaviridae Family

Scientists of Creative Biolabs are top talents from around the world, and their experience and creative ideas in the vaccine field make Creative Biolabs competitive in the vaccine industry. We have in-depth research on the viral vaccines of Bunyaviridae family and have developed a series of high-quality related products and services that are believed to meet your needs in the Bunyavirus vaccine research.

Bunyaviridae

Virus in the Bunyaviridae family is an enveloped, spherical virion with a diameter of approximately 90-100 nm. The genome of Bunyavirus is three single-stranded, linear, negative-sense or ambisense RNA fragments, S, M, and L, respectively. Wherein, the S fragment encodes a nucleocapsid protein, and further, the fragment could also encode a non-structural protein in some genera, and such non-structural protein is capable of interfering with the host's innate immune response. The M fragment encodes a glycoprotein and thus forms spikes on the surface of the virion. The L fragment encodes transcriptase and proteins involved in replication as well as RNA-dependent RNA polymerase (L protein). In addition to the polymerase activity, the L protein of Bunyavirus has endonuclease activity, which can cleave the messenger RNA of the cells, producing capped primers, and thereby initiating transcription of viral RNA. The envelope glycoprotein of Bunyaviruses is the decisive antigen that induces the production of neutralizing antibodies in the body, while the antigenicity of nucleocapsid protein is mainly related to complement fixation.

Rift Valley Fever Vaccine

Rift Valley Fever is a mosquito-borne zoonosis whose pathogen is the Rift Valley Fever Virus. The virus was isolated in 1930, since when, several large outbreaks have occurred in some African countries, causing great losses to livestock and humans. The disease is more severe in cattle and sheep and often leads to the death of newborn animals and the abortion of pregnant animals. People are usually able to heal themselves after being infected with the disease, but in rare cases, about 1-2% of the infected population will develop a serious disease, with mortality ranging from 20-50%. Studies have shown that the glycoprotein on the surface of the Rift Valley Fever Virus is the main virulence factor for the virus to adhere to target cells and initiate infection, and it also contains neutralizing epitopes of the virus. Therefore, the key target for designing the Rift Valley Fever vaccine is the glycoprotein on the surface of the Rift Valley Fever Virus.

Creative Biolabs is a pioneer in the vaccine industry. We have established a professional team, a series of mature platforms and a research and development system for decades of research and exploration. Today, our products and services have covered all aspects of bacteria, viruses, and cancer vaccines, and we are sure to provide you with the most satisfactory service.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.